Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Judson

Showing results (131-140 of 151) with videos related to

Pageof 16
Sort By:
The Lancet. Oncology|December 29, 2009
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyDavid Olmos, Sophie Postel-Vinay, L Rhoda Molife, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2012
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancerPaul Nathan, Martin Zweifel, Anwar R Padhani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2009
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumorsRuth Plummer, Laura Vidal, Melanie Griffin, et al.
Cancer Research|September 10, 2009
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agentsYuval Shaked, Terence Tang, Jill Woloszynek, et al.
Cancer Research|June 25, 2009
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomasIsabelle Ray-Coquard, Claire Cropet, Martine Van Glabbeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trialMarie-Cécile Le Deley, Michael Paulussen, Ian Lewis, et al.
Cancer Research|April 6, 2007
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycinAlison Maloney, Paul A Clarke, Soren Naaby-Hansen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2015
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trialHenk van den Berg, Michael Paulussen, Gwénaël Le Teuff, et al.
Oncotarget|October 24, 2018
Surrogate endpoints in advanced sarcoma trials: a meta-analysisMarion Savina, Saskia Litière, Antoine Italiano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumorsJosep Tabernero, Federico Rojo, Emiliano Calvo, et al.
Pageof 16

Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|December 29, 2009
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyDavid Olmos, Sophie Postel-Vinay, L Rhoda Molife, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2012
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancerPaul Nathan, Martin Zweifel, Anwar R Padhani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2009
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumorsRuth Plummer, Laura Vidal, Melanie Griffin, et al.
Cancer Research|September 10, 2009
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agentsYuval Shaked, Terence Tang, Jill Woloszynek, et al.
Cancer Research|June 25, 2009
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomasIsabelle Ray-Coquard, Claire Cropet, Martine Van Glabbeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trialMarie-Cécile Le Deley, Michael Paulussen, Ian Lewis, et al.
Cancer Research|April 6, 2007
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycinAlison Maloney, Paul A Clarke, Soren Naaby-Hansen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2015
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trialHenk van den Berg, Michael Paulussen, Gwénaël Le Teuff, et al.
Oncotarget|October 24, 2018
Surrogate endpoints in advanced sarcoma trials: a meta-analysisMarion Savina, Saskia Litière, Antoine Italiano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumorsJosep Tabernero, Federico Rojo, Emiliano Calvo, et al.
Pageof 16